Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analogues

Biochemical Pharmacology

Volumn 80, Issue 10, 2010, Pages 1580-1591

  Harvey, Brian H ^a   Duvenhage, Ingrid ^a   Viljoen, Francois ^a   Scheepers, Nellie ^a   Malan, Sarel F ^a,c   Wegener, Gregers ^b   Brink, Christiaan B ^a   Petzer, Jacobus P ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF THE WESTERN CAPE   (South Africa)

Author keywords

Antidepressant; Dopamine; Dual action; Methylene blue; Monoamine oxidase; Nitric oxide; Norepinephrine; Serotonin; Structural analogues

Indexed keywords

ACRIFLAVINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIDEPRESSANT AGENT; IMIPRAMINE; METHYLENE BLUE; METHYLENE GREEN; METHYLENE VIOLET; MONOAMINE DERIVATIVE; NITRIC OXIDE SYNTHASE; SEROTONIN; SODIUM CHLORIDE; TACRINE; THIONINE; UNCLASSIFIED DRUG; AMINE OXIDASE (FLAVIN CONTAINING); BIOGENIC AMINE; RECOMBINANT PROTEIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; DRUG ACTIVITY; DRUG EFFECT; FORCED SWIMMING TEST; IC 50; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; METHYLENE BLUE; MOLECULAR STRUCTURE; MONOAMINE OXIDASE; MOTOR ACTIVITY; NITRIC OXIDE SYNTHASE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SWIMMING;

EID: 77957016764     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.07.037     Document Type: Article

References (72)

1. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:593-602.
2. Kessler R.C., Chiu W.T., Demler O., Walters E.E. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 2005, 62:617-627.
3. Sartorius N., Baghai T.C., Baldwin D.S., Barrett B., Brand U., Fleischhacker W., et al. Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int J Neuropsychopharmacol 2007, 10(Suppl. 1):S1-207.
4. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
5. Manji H.K., Quiroz J.A., Sporn J., Payne J.L., Denicoff K., Gray A., et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003, 53:707-742.
6. Harvey B.H. Affective disorders and nitric oxide: a role in pathways to relapse refractoriness. Hum Psychopharmacol 1996, 11:309-319.
7. Bernstein H.G., Stanarius A., Baumann B., Henning H., Krell D., Danos P., et al. Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 1998, 83:867-875.
8. Suzuki E., Yagi G., Nakaki T., Kanba S., Asai M. Elevated plasma nitrate levels in depressive states. J Affec Dis 2001, 63:221-224.
9. Wegener G., Harvey B.H., Bonefeld B., Müller H.K., Volke V., Overstreet D.H., et al. Increased stress-evoked nitric oxide signalling in the Flinders sensitive line (FSL) rat: a genetic animal model of depression. Int J Neuropsychopharmacol 2010, 13:461-473.
10. Harkin A.J., Bruce K.H., Craft B., Paul I.A. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. Acute treatments are active in the forced swim test. Eur J Pharmacol 1999, 372:207-213.
11. Wegener G., Volke V., Harvey B.H., Rosenberg R. Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res 2003, 959:128-134.
12. Liebenberg N., Harvey B.H., Brand L., Brink C.B. Antidepressant-like properties of phosphodiesterase 5 inhibitors and cholinergic dependency in a genetic rat model of depression. Behav Pharmacol 2010, 21:540-547.
13. Heiberg I.L., Wegener G., Rosenberg R. Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res 2002, 134:479-484.
14. da Silva G.D., Matteussi A.S., dos Santos A.R., Calixto J.B., Rodrigues A.L. Evidence for dual effects of nitric oxide in the forced swimming test and in the tail suspension test in mice. Neuroreport 2000, 11:3699-3702.
15. Inan S.Y., Yalcin I., Aksu F. Dual effects of nitric oxide in the mouse forced swimming test: possible contribution of nitric oxide-mediated serotonin release and potassium channel modulation. Pharmacol Biochem Behav 2004, 77:457-464.
16. Kleppisch T., Feil R. cGMP signalling in the mammalian brain: role in synaptic plasticity and behaviour. Handb Exp Pharmacol 2009, 191:549-579.
17. Prast H., Philippu A. Nitric oxide as modulator of neuronal function. Prog Neurobiol 2001, 64:51-68.
18. Feil R., Kleppisch T. NO/cGMP-dependent modulation of synaptic transmission. Handb Exp Pharmacol 2008, 184:529-560.
19. Paige J.S., Jaffrey S.R. Pharmacologic manipulation of nitric oxide signaling: targeting NOS dimerization and protein-protein interactions. Curr Top Med Chem 2007, 7:97-114.
20. Garthwaite J., Boulton C.L. Nitric oxide signaling in the central nervous system. Annu Rev Physiol 1995, 57:683-706.
21. Moore P.K., Handy R.L. Selective inhibitors of neuronal nitric oxide synthase--is no NOS really good NOS for the nervous system?. Trends Pharmacol Sci 1997, 18:204-211.
22. Bodini P. Le bleu de methylene comme calmant chez les alienes. Semaine Med 1899, 7:56.
23. Eroglu L., Caglayan B. Anxiolytic and antidepressant properties of methylene blue in animal models. Pharmacol Res 1997, 36:381-385.
24. Narsapur S.L., Naylor G.J. Methylene blue. A possible treatment for manic depressive psychosis. J Affect Disord 1983 May 1, 5(2):155-161.
25. Naylor G.J., Smith A.H., Connelly P. A controlled trial of methylene blue in severe depressive illness. Biol Psychiatry 1987, 22:657-659.
26. Naylor G.J., Smith A.H., Connelly P. Methylene blue in mania. Biol Psychiatry 1988, 24:941-942.
27. Oz M, Lorke DE, Hasan M, Petroianu GA. Cellular and molecular actions of methylene blue in the nervous system. Med Res Rev 2010, doi:10.1002/med.20177 [Epub ahead of print].
28. Oxenkrug G.F., Sablin S.O., Requintina P.J. Effect of methylene blue and related redox dyes on monoamine oxidase activity; rat pineal content of N-acetylserotonin, melatonin, and related indoles; and righting reflex in melatonin-primed frogs. Ann NY Acad Sci 2007, 1122:245-252.
29. Ramsay R.R., Dunford C., Gillman P.K. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol 2007, 152:946-951.
30. Leonard B.E. Fundamentals of psychopharmacology 2003, John Wiley and Sons, Chichester UK. 3rd ed.
31. Luo D., Das S., Vincent S.R. Effects of methylene blue and LY83583 on neuronal nitric oxide synthase and NADPH-diaphorase. Eur J Pharmacol 1995, 290:247-251.
32. Volke V., Wegener G., Vasar E., Rosenberg R. Methylene blue inhibits hippocampal nitric oxide synthase activity in vivo. Brain Res 1999, 826:303-305.
33. Oz M., Lorke D.E., Petroianu G.A. Methylene blue and Alzheimer's disease. Biochem Pharmacol 2009, 78:927-932.
34. Millan M.J. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 2009, 6:53-77.
35. Detke M.J., Johnson J., Lucki I. Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Exp Clin Psychopharmacol 1997, 5:107-112.
36. Porsolt R.D., Brossard G., Hautbois C., Roux S. Models of affective illness: Forced Swimming and Tail Suspension Tests in Rodents. Current protocols in pharmacology 2000, 581-589. John Wiley & Sons Inc., New York. S.J. Enna, M. Williams, J.F. Barret, J.W. Ferkany, T. Kenakin, R.D. Porsolt (Eds.).
37. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002, 23:238-245.
38. 2A/C-receptors. Metab Brain Dis 2006, 21:211-220.
39. Harvey B.H., Jonker L.P., Brand L., Heenop M., Stein D.J. NMDA receptor involvement in imipramine withdrawal-associated effects on swim stress. GABA levels and NMDA receptor binding in rat hippocampus. Life Sci 2002, 71:43-54.
40. Sewell P., Hawking F. Chemotherapy of experimental filariasis. Br J Pharmacol Chemother 1950 Jun, 5(2):239-260.
41. Steinman R.R., Leonara J. Relationship of fluid transport through the dentin to the incidence of dental caries. J Dent Res 1971, 50:1536-1543.
42. Cousins M.S., Carriero D.L., Salamone J.D. Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs. Eur J Pharmacol 1997 Mar 19, 322(2-3):137-145.
43. Hawking F., Ormerod W.E., Thurston J.P., Webber W.A. The antifilarial action and toxicity of methylene violet and of other compounds of the phenosafranine series. Br J Pharmacol Chemother 1952 Sep, 7(3):494-508.
44. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978, 47:379-391.
45. Novaroli L., Reist M., Favre E., Carotti A., Catto M., Carrupt P.A. Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening. Bioorg Med Chem 2005, 13:6212-6217.
46. Chimenti F., Secci D., Bolasco A., Chimenti P., Bizzarri B., Granese A., et al. Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem 2009, 52:1935-1942.
47. Schmidit H.H.H.W., Kelm M. Determination of nitrite and nitrate by the Griess reaction. Methods in nitric oxide research 1996, 491-498. John Wiley and Sons, Chichester, England, UK. M. Feelisch, J.S. Stamler (Eds.).
48. Harvey B.H., Brand L., Jeeva Z., Stein D.J. Cortical/hippocampal monoamines, HPA-axis changes and aversive behavior following stress and restress in an animal model of post-traumatic stress disorder. Physiol Behav 2006, 87:881-890.
49. Baldessarini R.J. Drug therapy of depression and anxiety disorders. Goodman and Gilman's the pharmacological basis of therapeutics 2006, 429-459. McGraw-Hill Publishers. 11th ed. L.L. Brunton, J.S. Lazo, L.K. parker (Eds.).
50. Harvey B.H. The neurobiology and pharmacology of depression. S Afr Med J 1997, 87:540-550.
51. Harvey B.H., Duvenhage I., Petzer J.P., Malan S.F., Wegener G Monoamine oxidase-A inhibition by methylene blue and selected analogues and antidepressant effects in the rat forced swim test. Int J Neuropsychopharmacol 2010, (13 Supplement S1: 1-268, poster P-03-018).
52. Ng B.K., Cameron A.J., Liang R., Rahman H. Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review. Can J Anaesth 2008, 55:36-41.
53. Harkin A., Connor T.J., Burns M.P., Kelly J.P. Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. Eur Neuropsychopharmacol 2004, 14:274-281.
54. Jopek R., Kata M., Nowak G. The activity of rat brain nitric oxide synthase following chronic antidepressant treatment. Acta Pol Pharm 1999, 56:307-310.
55. Suzuki E., Nakaki T., Kanba S., Shintani F., Miyaoka H. Long-term imipramine treatment increases nitrate levels in the rat hypothalamus. Cell Mol Neurobiol 2003, 23:953-962.
56. Drevets W.C. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 2001, 11:240-249.
57. Liotti M., Mayberg H.S. The role of functional neuroimaging in the neuropsychology of depression. J Clin Exp Neuropsychol. 2001, 23:121-136.
58. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
59. Graeff F.G., Guimarães F.S., De Andrade T.G., Deakin J.F. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 1996, 54:129-141.
60. Koob G.F. Corticotropin-releasing factor, norepinephrine and stress. Biol Psychiatry 1999, 46:1176-1180.
61. Rosario L.A., Abercrombie E.D. Individual differences in behavioural reactivity: correlation with stress-induced nor-epinephrine efflux in the hippocampus of Sprague-Dawley rats. Brain Res Bull 1999, 48:595-602.
62. Finlay J.M., Zigmond M.J., Abercrombie E.D. Increased dopamine and norepinephrine release in medial pre-frontal cortex induced by acute and chronic stress: effects of diazepam. Neuroscience 1995, 64:619-628.
63. Sullivan G.M., Coplan J.D., Kent J.M., Gorman J.M. The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias. Biol Psychiatry 1999, 46:1205-1218.
64. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006, 59:1151-1159.
65. Wegener G., Volke V., Rosenberg R. Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo. Br J Pharmacol 2000, 130:575-580.
66. Karoum F., Korpi E.R., Linnoila M., Chuang L.W., Wyatt R.J. Reduced metabolism and turnover rates of rat brain dopamine, norepinephrine and serotonin by chronic desipramine and zimelidine treatments. Eur J Pharmacol 1984, 100:137-144.
67. Karolewicz B., Paul I.A., Antkiewicz-Michaluk L. Effect of NOS inhibitor on forced swim test and neurotransmitters turnover in the mouse brain. Pol J Pharmacol 2001, 53:587-596.
68. Blier P., Chaput Y., de Montigny C. Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: an electrophysiological study in the rat brain. Naunyn Schmied Arch Pharmacol 1988, 337:246-254.
69. Haddjeri N., Blier P., de Montigney C. Long-term antidepressant treatments result in a tonic activation of forebrain 5HT1A receptors. J Neurosci 1998, 18:10150-10156.
70. Harvey B.H. Is major depressive disorder a metabolic encephalopathy?. Hum Psychopharmacol 2008, 23:371-384.
71. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008, 11:851-876.
72. Mokoena M.L., Harvey B.H., Oliver D.W., Brink C.B. Ozone modulates the effects of imipramine on immobility in the forced swim test, and nonspecific parameters of hippocampal oxidative stress in the rat. Metab Brain Dis 2010, 25:125-133.